Reporting on American College of Obstetricians and Gynecologists guidance advises people planning pregnancy while using GLP-1 medicines to arrange discontinuation with their prescriber, generally one to two months beforehand depending on the drug. Use during pregnancy is discouraged because safety data are limited, but exposure does not itself establish fetal harm. During breastfeeding, treatment need and infant growth require individual assessment, with extra caution for newborns and premature infants. Drug persistence and formulations differ, so discuss pregnancy plans rather than applying one stop or restart date to every product.